Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the Akt inhibitor MK2206 in patients with previously treated metastatic or locally advanced colon or rectal cancer unsu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colon Mucinous Adenocarcinoma
• Colon Signet Ring Cell Adenocarcinoma
• Rectal Cancer
• Rectal Mucinous Adenocarcinoma
• Rectal Signet Ring Cell Adenocarcinoma

Drugs mentioned

• MK2206 (MK2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-30